SCHEMBL6416976

SCHEMBL6416976

COc1ccc(/C=N/Nc2nc3nonc3nc2NCc2ccccc2)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.51
MAOB P27338 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE7A Q13946 1/20 0.45
GAA P10253 4/20 0.45
EGFR P00533 2/20 0.44
RAB9A P51151 5/20 0.42
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
NPC1 O15118 3/20 0.42
KDM4E B2RXH2 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432987 1.00 ADORA2A (0.51) ADORA2AMAOBPDE4BPDE7AGAA
SCHEMBL6433407 0.93 ADORA2A (0.51) ADORA2AMAOBGAAEGFRRAB9A
SCHEMBL6433398 0.93 ADORA2A (0.51) ADORA2AMAOBGAAEGFRRAB9A
SCHEMBL6415725 0.89 GAA (0.51) PDE4BGAARAB9AMAPTSMN1; SMN2
SCHEMBL6431543 0.85 DDX3X (0.49) ADORA2AMAOBGAAEGFRRAB9A
SCHEMBL6414665 0.85 DDX3X (0.53) GAARAB9AMAPTSMN1; SMN2TDP1
SCHEMBL6413690 0.82 MAPT (0.51) ADORA2AGAARAB9AMAPTSMN1; SMN2
SCHEMBL6413685 0.82 MAPT (0.51) ADORA2AGAARAB9AMAPTSMN1; SMN2
SCHEMBL6436303 0.81 GAA (0.58) ADORA2AGAARAB9AMAPTSMN1; SMN2
SCHEMBL6436307 0.81 GAA (0.58) ADORA2AGAARAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 ADORA2A 269/4885MAOB 746/4885PDE4B 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.